+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibiotic Resistance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Antibiotic Resistance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Antibiotic Resistance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 215 Pages
  • July 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5918300
Description Jump to:
The global antibiotic resistance market is poised for significant expansion, projected to grow from US$ 11.3 billion in 2025 to US$ 17.1 billion by 2032, registering a CAGR of 6.10% during the forecast period. Driven by the alarming increase in drug-resistant infections and expanding global health initiatives, the market continues to be a critical area of innovation and investment.

Market Insights

The rise of antibiotic-resistant pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, and Pseudomonas aeruginosa has significantly elevated the need for novel therapeutics and diagnostic tools. Public health organizations like the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have identified antimicrobial resistance (AMR) as a top global threat. In response, major pharmaceutical and biotech companies are increasing R&D investments, spurring advancements in antibiotic development, stewardship programs, and combination therapies.

Market Drivers

The antibiotic resistance market is being driven by several critical factors:

  • Increasing incidence of multidrug-resistant infections in hospitals and communities
  • Overuse and misuse of antibiotics in both human medicine and livestock production
  • Growing investments in research from public and private sectors
  • Adoption of AI in drug discovery and rapid diagnostic solutions
  • Strengthening global policy frameworks and funding programs targeting AMR
In particular, government-backed initiatives, such as the launch of India's indigenous antibiotic Nafithromycin and the U.S.-based Global AMR Innovation Fund, are creating a fertile environment for innovation.

Business Opportunity

Innovations in bacteriophage therapy, next-generation β-lactamase inhibitors, and combination drug regimens are opening new market frontiers. For instance, in, Venatorx Pharmaceuticals’ taniborbactam received fast-track FDA approval, while Merck’s cefiderocol continued to show promise against carbapenem-resistant infections. Additionally, collaborative global research projects-such as the Loughborough University-led effort on E. coli in the U.K. and India-are exploring virus-based alternatives to traditional antibiotics.

The rise in resistance-related deaths and prolonged hospital stays are compelling healthcare systems to invest in targeted therapies. This is anticipated to boost demand in both developed and emerging markets.

Regional Analysis

North America is set to lead the global antibiotic resistance market, accounting for a substantial share due to a high prevalence of drug-resistant infections and robust healthcare infrastructure. The region benefits from supportive government initiatives, awareness campaigns, and reimbursement policies, especially in the United States.

Europe is focusing on fast-track antibiotic approvals and advanced clinical management for infections such as complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HABP/VABP). Countries like Spain and Italy are actively involved in multinational surveillance and research programs to mitigate the growing burden.

Asia Pacific, particularly India and China, is emerging as a vital hub for antibiotic innovation and production. With increasing fatalities from superbugs and growing pharmaceutical manufacturing capabilities, the region is expected to witness significant growth. Government support and public-private collaborations are catalyzing the development of new treatment options.

Key Players

The antibiotic resistance market features a competitive Analysis dominated by global leaders and emerging biotech firms. Companies are focusing on R&D, strategic partnerships, and geographical expansion to consolidate their market presence. Notable players include:
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Takara Bio, Inc.
  • QIAGEN N.V.
  • Pall Corporation
  • Eppendorf Corporate
  • Tarsons Products Pvt. Ltd.
  • Applied Biological Materials Inc.
  • Greiner AG
  • Brooks Life Sciences
  • Corning Incorporated
  • Cytiva
  • PerkinElmer

Market Segmentation

By Drug Class

  • Beta Lactam Antibiotics
  • Tetracyclines
  • Lipoglycopeptides
  • Combination Therapies
  • Cephalosporins
  • Oxazolidinones
  • Others

By Pathogen

  • Staphylococcus aureus
  • Streptococcus pneumonia
  • Vancomycin-resistant Enterococcus
  • Neisseria gonorrhoeae
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Mycobacterium tuberculosis
  • Acinetobacter
  • Clostridium difficile
  • Others

By Disease

  • Community Acquired Bacterial Pneumonia (CABP)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Complicated Urinary Tract Infections (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
  • Blood Stream Infections (BSI)
  • Abdominal Infection and Diarrhea (CDI & Shigella)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Others

By Mechanism of Action

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Antibiotic Resistance Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Antibiotic Resistance Market Outlook, 2019-2032
3.1. Global Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Beta Lactam Antibiotic
3.1.1.2. Cephalosporins
3.1.1.3. Quinolones Antibiotics
3.1.1.4. Macrolide Antibiotics
3.1.1.5. Tetracyclines
3.1.1.6. Oxazolidinones
3.1.1.7. Others
3.2. Global Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Staphylococcus aureus
3.2.1.2. Streptococcus pneumonia
3.2.1.3. Neisseria gonorrhoeae
3.2.1.4. Enterococcus faecium
3.2.1.5. Escherichia coli
3.2.1.6. Klebsiella Pneumonia
3.2.1.7. Shigella
3.2.1.8. Clostridium difficile
3.2.1.9. Others
3.3. Global Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
3.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
3.3.1.3. Complicated Urinary Tract Infections (CUTI)
3.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
3.3.1.5. Blood Stream Infections (BSI)
3.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
3.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
3.3.1.8. Drug Resistant Gonorrhoeae
3.4. Global Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Cell Wall Synthesis Inhibitors
3.4.1.2. Protein Synthesis Inhibitors
3.4.1.3. DNA Synthesis Inhibitors
3.4.1.4. RNA Synthesis Inhibitors
3.4.1.5. Others
3.5. Others Global Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. Hospitals Pharmacies
3.5.1.2. Retail Pharmacies
3.5.1.3. Online Pharmacies
3.6. Global Antibiotic Resistance Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America Antibiotic Resistance Market Outlook, 2019-2032
4.1. North America Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Beta Lactam Antibiotic
4.1.1.2. Cephalosporins
4.1.1.3. Quinolones Antibiotics
4.1.1.4. Macrolide Antibiotics
4.1.1.5. Tetracyclines
4.1.1.6. Oxazolidinones
4.1.1.7. Others
4.2. North America Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Staphylococcus aureus
4.2.1.2. Streptococcus pneumonia
4.2.1.3. Neisseria gonorrhoeae
4.2.1.4. Enterococcus faecium
4.2.1.5. Escherichia coli
4.2.1.6. Klebsiella Pneumonia
4.2.1.7. Shigella
4.2.1.8. Clostridium difficile
4.2.1.9. Others
4.3. North America Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
4.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
4.3.1.3. Complicated Urinary Tract Infections (CUTI)
4.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
4.3.1.5. Blood Stream Infections (BSI)
4.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
4.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
4.3.1.8. Drug Resistant Gonorrhoeae
4.4. North America Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Cell Wall Synthesis Inhibitors
4.4.1.2. Protein Synthesis Inhibitors
4.4.1.3. DNA Synthesis Inhibitors
4.4.1.4. RNA Synthesis Inhibitors
4.4.1.5. Others
4.5. North America Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. Hospitals Pharmacies
4.5.1.2. Retail Pharmacies
4.5.1.3. Online Pharmacies
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.6.1. Key Highlights
4.6.1.1. U.S. Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
4.6.1.2. U.S. Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
4.6.1.3. U.S. Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
4.6.1.4. U.S. Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
4.6.1.5. U.S. Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
4.6.1.6. Canada Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
4.6.1.7. Canada Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
4.6.1.8. Canada Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
4.6.1.9. Canada Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
4.6.1.10. Canada Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Antibiotic Resistance Market Outlook, 2019-2032
5.1. Europe Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Beta Lactam Antibiotic
5.1.1.2. Cephalosporins
5.1.1.3. Quinolones Antibiotics
5.1.1.4. Macrolide Antibiotics
5.1.1.5. Tetracyclines
5.1.1.6. Oxazolidinones
5.1.1.7. Others
5.2. Europe Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Staphylococcus aureus
5.2.1.2. Streptococcus pneumonia
5.2.1.3. Neisseria gonorrhoeae
5.2.1.4. Enterococcus faecium
5.2.1.5. Escherichia coli
5.2.1.6. Klebsiella Pneumonia
5.2.1.7. Shigella
5.2.1.8. Clostridium difficile
5.2.1.9. Others
5.3. Europe Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
5.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
5.3.1.3. Complicated Urinary Tract Infections (CUTI)
5.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
5.3.1.5. Blood Stream Infections (BSI)
5.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
5.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
5.3.1.8. Drug Resistant Gonorrhoeae
5.4. Europe Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Cell Wall Synthesis Inhibitors
5.4.1.2. Protein Synthesis Inhibitors
5.4.1.3. DNA Synthesis Inhibitors
5.4.1.4. RNA Synthesis Inhibitors
5.4.1.5. Others
5.5. Europe Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Hospitals Pharmacies
5.5.1.2. Retail Pharmacies
5.5.1.3. Online Pharmacies
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.6.1. Key Highlights
5.6.1.1. Germany Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.2. Germany Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.3. Germany Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.4. Germany Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.5. Germany Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.6. U.K. Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.7. U.K. Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.8. U.K. Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.9. U.K. Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.10. U.K. Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.11. France Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.12. France Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.13. France Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.14. France Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.15. France Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.16. Italy Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.17. Italy Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.18. Italy Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.19. Italy Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.20. Italy Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.21. Turkey Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.22. Turkey Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.23. Turkey Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.24. Turkey Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.25. Turkey Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.26. Russia Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.27. Russia Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.28. Russia Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.29. Russia Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.30. Russia Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.1.31. Rest of Europe Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
5.6.1.32. Rest of Europe Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
5.6.1.33. Rest of Europe Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
5.6.1.34. Rest of Europe Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
5.6.1.35. Rest of Europe Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Antibiotic Resistance Market Outlook, 2019-2032
6.1. Asia Pacific Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Beta Lactam Antibiotic
6.1.1.2. Cephalosporins
6.1.1.3. Quinolones Antibiotics
6.1.1.4. Macrolide Antibiotics
6.1.1.5. Tetracyclines
6.1.1.6. Oxazolidinones
6.1.1.7. Others
6.2. Asia Pacific Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Staphylococcus aureus
6.2.1.2. Streptococcus pneumonia
6.2.1.3. Neisseria gonorrhoeae
6.2.1.4. Enterococcus faecium
6.2.1.5. Escherichia coli
6.2.1.6. Klebsiella Pneumonia
6.2.1.7. Shigella
6.2.1.8. Clostridium difficile
6.2.1.9. Others
6.3. Asia Pacific Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
6.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
6.3.1.3. Complicated Urinary Tract Infections (CUTI)
6.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
6.3.1.5. Blood Stream Infections (BSI)
6.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
6.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
6.3.1.8. Drug Resistant Gonorrhoeae
6.4. Asia Pacific Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Cell Wall Synthesis Inhibitors
6.4.1.2. Protein Synthesis Inhibitors
6.4.1.3. DNA Synthesis Inhibitors
6.4.1.4. RNA Synthesis Inhibitors
6.4.1.5. Others
6.5. Asia Pacific Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. Hospitals Pharmacies
6.5.1.2. Retail Pharmacies
6.5.1.3. Online Pharmacies
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.6.1. Key Highlights
6.6.1.1. China Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.2. China Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.3. China Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.4. China Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.5. China Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.1.6. Japan Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.7. Japan Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.8. Japan Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.9. Japan Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.10. Japan Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.1.11. South Korea Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.12. South Korea Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.13. South Korea Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.14. South Korea Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.15. South Korea Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.1.16. India Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.17. India Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.18. India Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.19. India Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.20. India Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.1.21. Southeast Asia Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.22. Southeast Asia Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.23. Southeast Asia Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.24. Southeast Asia Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.25. Southeast Asia Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.1.26. Rest of Asia Pacific Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
6.6.1.27. Rest of Asia Pacific Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
6.6.1.28. Rest of Asia Pacific Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
6.6.1.29. Rest of Asia Pacific Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
6.6.1.30. Rest of Asia Pacific Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Antibiotic Resistance Market Outlook, 2019-2032
7.1. Latin America Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Beta Lactam Antibiotic
7.1.1.2. Cephalosporins
7.1.1.3. Quinolones Antibiotics
7.1.1.4. Macrolide Antibiotics
7.1.1.5. Tetracyclines
7.1.1.6. Oxazolidinones
7.1.1.7. Others
7.2. Latin America Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
7.2.1.1. Staphylococcus aureus
7.2.1.2. Streptococcus pneumonia
7.2.1.3. Neisseria gonorrhoeae
7.2.1.4. Enterococcus faecium
7.2.1.5. Escherichia coli
7.2.1.6. Klebsiella Pneumonia
7.2.1.7. Shigella
7.2.1.8. Clostridium difficile
7.2.1.9. Others
7.3. Latin America Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
7.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
7.3.1.3. Complicated Urinary Tract Infections (CUTI)
7.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
7.3.1.5. Blood Stream Infections (BSI)
7.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
7.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
7.3.1.8. Drug Resistant Gonorrhoeae
7.4. Latin America Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Cell Wall Synthesis Inhibitors
7.4.1.2. Protein Synthesis Inhibitors
7.4.1.3. DNA Synthesis Inhibitors
7.4.1.4. RNA Synthesis Inhibitors
7.4.1.5. Others
7.5. Latin America Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Hospitals Pharmacies
7.5.1.2. Retail Pharmacies
7.5.1.3. Online Pharmacies
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.6.1. Key Highlights
7.6.1.1. Brazil Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
7.6.1.2. Brazil Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
7.6.1.3. Brazil Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
7.6.1.4. Brazil Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
7.6.1.5. Brazil Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
7.6.1.6. Mexico Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
7.6.1.7. Mexico Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
7.6.1.8. Mexico Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
7.6.1.9. Mexico Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
7.6.1.10. Mexico Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
7.6.1.11. Argentina Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
7.6.1.12. Argentina Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
7.6.1.13. Argentina Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
7.6.1.14. Argentina Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
7.6.1.15. Argentina Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
7.6.1.16. Rest of Latin America Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
7.6.1.17. Rest of Latin America Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
7.6.1.18. Rest of Latin America Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
7.6.1.19. Rest of Latin America Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
7.6.1.20. Rest of Latin America Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Antibiotic Resistance Market Outlook, 2019-2032
8.1. Middle East & Africa Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Beta Lactam Antibiotic
8.1.1.2. Cephalosporins
8.1.1.3. Quinolones Antibiotics
8.1.1.4. Macrolide Antibiotics
8.1.1.5. Tetracyclines
8.1.1.6. Oxazolidinones
8.1.1.7. Others
8.2. Middle East & Africa Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Staphylococcus aureus
8.2.1.2. Streptococcus pneumonia
8.2.1.3. Neisseria gonorrhoeae
8.2.1.4. Enterococcus faecium
8.2.1.5. Escherichia coli
8.2.1.6. Klebsiella Pneumonia
8.2.1.7. Shigella
8.2.1.8. Clostridium difficile
8.2.1.9. Others
8.3. Middle East & Africa Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
8.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
8.3.1.3. Complicated Urinary Tract Infections (CUTI)
8.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
8.3.1.5. Blood Stream Infections (BSI)
8.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
8.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
8.3.1.8. Drug Resistant Gonorrhoeae
8.4. Middle East & Africa Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Cell Wall Synthesis Inhibitors
8.4.1.2. Protein Synthesis Inhibitors
8.4.1.3. DNA Synthesis Inhibitors
8.4.1.4. RNA Synthesis Inhibitors
8.4.1.5. Others
8.5. Middle East & Africa Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. Hospitals Pharmacies
8.5.1.2. Retail Pharmacies
8.5.1.3. Online Pharmacies
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.6.1. Key Highlights
8.6.1.1. GCC Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
8.6.1.2. GCC Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
8.6.1.3. GCC Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
8.6.1.4. GCC Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
8.6.1.5. GCC Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
8.6.1.6. South Africa Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
8.6.1.7. South Africa Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
8.6.1.8. South Africa Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
8.6.1.9. South Africa Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
8.6.1.10. South Africa Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
8.6.1.11. Egypt Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
8.6.1.12. Egypt Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
8.6.1.13. Egypt Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
8.6.1.14. Egypt Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
8.6.1.15. Egypt Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
8.6.1.16. Nigeria Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
8.6.1.17. Nigeria Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
8.6.1.18. Nigeria Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
8.6.1.19. Nigeria Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
8.6.1.20. Nigeria Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
8.6.1.21. Rest of Middle East & Africa Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2019-2032
8.6.1.22. Rest of Middle East & Africa Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2019-2032
8.6.1.23. Rest of Middle East & Africa Antibiotic Resistance Market by Disease, Value (US$ Bn), 2019-2032
8.6.1.24. Rest of Middle East & Africa Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2019-2032
8.6.1.25. Rest of Middle East & Africa Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2019-2032
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Species vs by Pathogen Heat map
9.2. Manufacturer vs by Pathogen Heat map
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Thermo Fisher Scientific, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Merck KgaA
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bio-Rad Laboratories, Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Takara Bio, Inc.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. QIAGEN N.V.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Pall Corporation
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Eppendorf Corporate
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Tarsons Products PVT. LTD.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Applied Biological Materials Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Greiner AG
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Brooks Life Sciences
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Corning Incorporated
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Cytiva
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. PerkinElmer
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Bio-Rad Laboratories, Inc.
  • Takara Bio, Inc.
  • QIAGEN N.V.
  • Pall Corporation
  • Eppendorf Corporate
  • Tarsons Products PVT. LTD.
  • Applied Biological Materials Inc.
  • Greiner AG
  • Brooks Life Sciences
  • Corning Incorporated
  • Cytiva
  • PerkinElmer

Related Topics

Related Reports

Antibiotic Resistance Market Report 2025 - Product Image

Antibiotic Resistance Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Antibiotic Resistance Therapeutics Market 2025-2029 - Insights by Pathogen and Therapy Type, with Situation Analysis, Executive, and Investor Guides - Product Image

Antibiotic Resistance Therapeutics Market 2025-2029 - Insights by Pathogen and Therapy Type, with Situation Analysis, Executive, and Investor Guides

  • Report
  • 470 Pages
  • Global
From
Antibiotic Resistance Market by Product Type, Test Type, Application, End Use, Resistance Mechanism - Global Forecast to 2030 - Product Image

Antibiotic Resistance Market by Product Type, Test Type, Application, End Use, Resistance Mechanism - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
2025 Global Forecast for Antibiotic Resistance Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Antibiotic Resistance Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.